$5.01
63.22% today
Nasdaq, Feb 28, 05:20 pm CET
ISIN
US68621F1021
Symbol
ORGO

Organogenesis Holdings Stock price

$3.07
-0.67 17.91% 1M
+0.13 4.42% 6M
-0.13 4.06% YTD
-0.51 14.25% 1Y
-4.37 58.74% 3Y
-0.83 21.28% 5Y
-6.68 68.51% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.18 5.54%
ISIN
US68621F1021
Symbol
ORGO
Sector

Key metrics

Market capitalization $385.98m
Enterprise Value $397.43m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 102.17
EV/Sales (TTM) EV/Sales 0.87
P/S ratio (TTM) P/S ratio 0.85
P/B ratio (TTM) P/B ratio 1.46
Revenue growth (TTM) Revenue growth 1.34%
Revenue (TTM) Revenue $455.04m
EBIT (operating result TTM) EBIT $11.95m
Free Cash Flow (TTM) Free Cash Flow $3.89m
Cash position $94.93m
EPS (TTM) EPS $-0.06
P/E forward negative
P/S forward 0.88
EV/Sales forward 0.90
Short interest 30.36%
Show more

Is Organogenesis Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Organogenesis Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Organogenesis Holdings forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Organogenesis Holdings forecast:

Buy
75%
Hold
25%

Financial data from Organogenesis Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
455 455
1% 1%
100%
- Direct Costs 130 130
7% 7%
28%
325 325
1% 1%
72%
- Selling and Administrative Expenses 238 238
0% 0%
52%
- Research and Development Expense 51 51
15% 15%
11%
37 37
20% 20%
8%
- Depreciation and Amortization 25 25
17% 17%
6%
EBIT (Operating Income) EBIT 12 12
52% 52%
3%
Net Profit -7.38 -7.38
157% 157%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Organogenesis Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organogenesis Holdings Stock News

Neutral
Seeking Alpha
about 15 hours ago
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Gary S. Gillheeney, Sr. – President and Chief Executive Officer Dave Francisco – Chief Financial Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Markets Ross Osborn – Cantor Fitzgerald Ryan Zimmerman – BTIG Operator Please standby.
Neutral
GlobeNewsWire
about 20 hours ago
CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended Dece...
Neutral
GlobeNewsWire
about one month ago
CANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2024 financial results will be reported after the market c...
More Organogenesis Holdings News

Company Profile

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Head office United States
CEO Gary Gillheeney
Employees 862
Founded 1985
Website www.organogenesis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today